Loading…
Aprea Therapeutics, Inc. is projected to rise to $0.752 by 2027, a +26% move from its current price of $0.5977. APRE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.5809 | $0.5981 | $0.6157 | +0.06% |
| Aug 6 | $0.5742 | $0.5984 | $0.6236 | +0.12% |
| Aug 7 | $0.5693 | $0.5988 | $0.6298 | +0.18% |
| Aug 8 | $0.5652 | $0.5991 | $0.6351 | +0.24% |
| Aug 9 | $0.5617 | $0.5995 | $0.6398 | +0.30% |
| Aug 10 | $0.5585 | $0.5998 | $0.6442 | +0.36% |
| Aug 11 | $0.5557 | $0.6002 | $0.6483 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5557 | $0.6002 | $0.6483 | +0.42% |
| Week 2 | $0.5404 | $0.6027 | $0.6721 | +0.83% |
| Week 3 | $0.5295 | $0.6052 | $0.6916 | +1.25% |
| Week 4 | $0.5209 | $0.6077 | $0.709 | +1.67% |
| Week 5 | $0.5136 | $0.6102 | $0.725 | +2.10% |
| Week 6 | $0.5073 | $0.6128 | $0.7401 | +2.52% |
| Week 7 | $0.5018 | $0.6153 | $0.7545 | +2.95% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics that target DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers, and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
The company is headquartered in Doylestown, Pennsylvania, and is categorized in Healthcare.
The description places Aprea in the Healthcare sector as it advances cancer therapeutics through clinical development, with a focus on synthetic lethality approaches targeting DNA damage response pathways. The narrative highlights its two lead programs and the centralized location of its headquarters as context for investors and stakeholders.
Overall, this profile presents a small clinical-stage biopharmaceutical company with active Phase 1/2 trials and a focused scientific strategy anchored by WEE1 and ATR targets."
APRE trades at $0.6137. Its market cap is $7.6M and its rank is 4934. The forecast outlook shows a path of rising averages and higher price potential over time, with 2026 average at $0.6137 and 2050 average at $2.26, and max forecasts climbing to $4.50 by 2050.
In 2026 the max forecast is $0.8279 and the 2026 forecast carries a Neutral sentiment; from 2027 onward, forecasts shift to a Bullish stance with rising averages and upside potential (e.g., 2027 avg $0.7838 and 2030 avg $0.8006, reaching a 2050 max of $4.50).
A major floor 20.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 38.5% above — a clean break opens room to run.
A major ceiling 67.3% above — clearing it would confirm fresh momentum.
Key APRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.623 | Sell | $0.6273 | Sell |
| MA 10 | $0.6359 | Sell | $0.6421 | Sell |
| MA 20 | $0.6821 | Sell | $0.6735 | Sell |
| MA 50 | $0.753 | Sell | $0.7321 | Sell |
| MA 100 | $0.7869 | Sell | $0.7942 | Sell |
| MA 200 | $0.9011 | Sell | $0.9993 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.40 | Neutral |
| Stoch RSI (14) | 26.82 | Neutral |
| CCI (20) | -89.61 | Neutral |
| Williams %R (14) | -94.74 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -11.17 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 5.26 | Buy |
| TRIX (15) | -0.71 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 27.12 | Buy |
| Momentum (10) | -0.09 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.62 | Sell |
| ADX (14) | 21.31 | Sell |
| ATR (14) | 0.02 | Info |
Near-term technical picture is Bearish based on the current signal and RSI. RSI14 is 30, signaling subdued momentum. SMA50 is $0.7784 and SMA200 is $0.9217, showing the recent price action below the longer-term average trend.
Support sits at $0.625 and resistance at $0.828, with the 30-day price range ranging from $0.4944 to $0.7618. The combination of bearish sentiment with nearby support and resistance levels defines a cautious near-term outlook for APRE.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.59 | $0.5977 | $0.7926 | 0% | Neutral | |
| $0.5963 | $0.752 | $1.00 | +26% | Bullish | |
| $0.588 | $0.7645 | $1.06 | +28% | Bullish | |
| $0.5867 | $0.7823 | $1.12 | +31% | Bullish | |
| $0.5733 | $0.7815 | $1.15 | +31% | Bullish | |
| $0.5652 | $0.7862 | $1.18 | +32% | Bullish | |
| $0.5587 | $0.7919 | $1.22 | +33% | Bullish | |
| $0.6355 | $0.9168 | $1.43 | +53% | Bullish | |
| $0.7502 | $1.10 | $1.75 | +84% | Bullish | |
| $0.7327 | $1.09 | $1.76 | +83% | Bullish | |
| $0.9073 | $1.46 | $2.51 | +144% | Bullish | |
| $1.26 | $2.29 | $4.34 | +284% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.59 | $0.5977 | $0.7021 | +0.00% |
| September 2026 | $0.5092 | $0.6032 | $0.7354 | +0.93% |
| October 2026 | $0.5287 | $0.6309 | $0.778 | +4.59% |
| November 2026 | $0.5233 | $0.6283 | $0.782 | -0.42% |
| December 2026 | $0.5231 | $0.6315 | $0.7926 | +0.51% |
Click any year to see its month-by-month APRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect APRE to range from $0.59 to $0.7926 through 2026. The $0.5977 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The APRE price prediction for 2027 points to an average of $0.752 (low $0.5963, high $1.00) — a potential gain of +26% on today's $0.5977. Momentum favours further upside here.
In 2028, APRE is projected to trade between $0.588 and $1.06, averaging $0.7645 — a potential gain of +28% from today's $0.5977. That is up +2% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Aprea Therapeutics, Inc.'s 2029 outlook centres on $0.7823, within a $0.5867 to $1.12 range. That is up +2% on the projected 2028 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2030, APRE could reach as high as $1.15, with a base case around $0.7815 and support toward $0.5733 — roughly +31% from $0.5977. Buyers look set to stay in control over this stretch.
Expect APRE to range from $0.5652 to $1.18 through 2031. The $0.7862 average target implies a +32% move from current prices. That is up +1% on the projected 2030 average. Momentum favours further upside here.
The APRE price prediction for 2032 points to an average of $0.7919 (low $0.5587, high $1.22) — a potential gain of +33% on today's $0.5977. Buyers look set to stay in control over this stretch.
In 2033, APRE is projected to trade between $0.6355 and $1.43, averaging $0.9168 — a potential gain of +53% from today's $0.5977. That is up +16% on the projected 2032 average. Momentum favours further upside here.
Aprea Therapeutics, Inc.'s 2034 outlook centres on $1.10, within a $0.7502 to $1.75 range. That is up +20% on the projected 2033 average. That marks a +84% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, APRE could reach as high as $1.76, with a base case around $1.09 and support toward $0.7327 — roughly +83% from $0.5977. Momentum favours further upside here.
Expect APRE to range from $0.9073 to $2.51 through 2040. The $1.46 average target implies a +144% move from current prices. That is up +33% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The APRE price prediction for 2050 points to an average of $2.29 (low $1.26, high $4.34) — a potential gain of +284% on today's $0.5977. Momentum favours further upside here.
Investing $1,000 in APRE today (≈ 1,673.080141 APRE) could be worth
$3,836.57
+$2,836.57 (+284%) by 2050 · US Dollar
Based on the average projected APRE price of $2.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APREwould be worth at today's price.
$1,000 invested in APRE on Jul 31, 2025 (≈ 588.235278 APRE) would be worth
$351.59
-$648.41 (-64.8%) today · 0.35× · US Dollar
Based on a APRE entry price of $1.7 vs. today's $0.5977.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.632 | $945.73 | -5.4% |
| 1 month ago | $0.745 | $802.28 | -19.8% |
| 3 months ago | $0.818 | $730.68 | -26.9% |
| 6 months ago | $0.751 | $795.87 | -20.4% |
| 1 year ago | $1.7 | $351.59 | -64.8% |
| All time (5.0y) ago | $86 | $6.95 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APRE forecast.
Our base-case forecast reaches $1.20 around 2040.
Implied market cap at $1.20: $14.86M
The multi-year forecast shows a bullish trajectory with rising average prices across the horizon. The 2026 average is $0.6137, and the 2030 average is $0.8006, with the 2040 average at $1.44 and the 2050 average at $2.26. Max forecast prices also rise, reaching $1.21 in 2030, $2.58 in 2040, and $4.50 in 2050.
This implies upside potential from the near term, culminating in a substantial long-term gain relative to today’s price.
ROI figures follow a similar ascent: 2027 ROI 27.7%, 2028 ROI 27.5%, 2029 ROI 31.9%, 2030 ROI 30.5%, 2031 ROI 27.4%, 2032 ROI 28.7%, 2033 ROI 49.6%, 2034 ROI 81%, 2035 ROI 80.6%, 2040 ROI 134.3%, and 2050 ROI 269%. Sentiment shifts from Neutral in 2026 to Bullish from 2027 onward, indicating growing conviction in higher future prices.
These figures are estimates and not guarantees. The outlook is subject to market, clinical, and regulatory risks that could affect actual outcomes.
Tap a question to reveal the answer.
Avg $0.8006; min $0.5734; max $1.21; ROI 30.5%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with ROIs of 27.7% (2027), 27.5% (2028), 31.9% (2029), 30.5% (2030), rising to 269% by 2050. The 2026 view is Neutral with ROI 0%. These are estimates, not guarantees.
Yes. The 2040 max forecast is $2.58, indicating a potential price above $2 by 2040.
Max $4.50.
Avg $0.6137; min $0.59; max $0.8279; sentiment NEUTRAL; ROI 0%.
Aprea Therapeutics, Inc. Community Discussion
0Share your Aprea Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.